Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia

Abstract Myeloproliferative neoplasms (MPNs) are clonal disorders, derived from abnormal hematopoietic stem cells and result in an excessive production of blood cells. This MPN group of conditions encompasses different diseases with overlapping clinical and biologic similarities. The majority of the...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of medical and paediatric oncology 2018-10, Vol.39 (4), p.503-515
Main Authors: Agarwal, Mohan B, Malhotra, Hemant, Chakarborti, Prantar, Varma, Neelam, Mathews, Vikram, Bhattacharyya, Jina, Seth, Tulika, Gyathri, K, Menon, Hari, Subramanian, P G, Sharma, Ajay K, Bhattacharyya, Maitreyee, Mehta, Jay, Shah, Sandeep, Gogoi, P K, Nair, Reena, Agarwal, Usha, Varma, Subhash, Prasad, S V V S, Mishra, Deepak K
Format: Article
Language:English
Subjects:
Anemia
Blood
Blood cancer
Blood platelets
Bone marrow
Care and treatment
Diagnosis
Experts
Hemorrhage
Leukemia
Mutation
Myeloproliferative disorders
Pathology
Practice guidelines (Medicine)
Pregnancy
Review Article
Stillbirth
Tumors
Working groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Myeloproliferative neoplasms (MPNs) are clonal disorders, derived from abnormal hematopoietic stem cells and result in an excessive production of blood cells. This MPN group of conditions encompasses different diseases with overlapping clinical and biologic similarities. The majority of the conventional therapies of MPN are palliative in nature. However, with the discovery of Janus Kinase 2 (JAK2) mutation and development of targeted JAK1/2 inhibition therapy, the therapeutic options in treatment landscape have changed dramatically. This article presents the revised Indian MPNs Working Group consensus recommendations. It highlights and brings into attention about the recent findings that have defined the state of the art of the diagnosis and therapy in the MPN area, including identification of the new driver and prognostic mutations, treatment goals in the management of myelofibrosis and polycythemia vera (PV), role of the recently approved, targeted tyrosine kinase inhibitor ruxolitinib in PV, and special issues such MPN consideration in patients with splenic vein thrombosis and the management of the disease in pregnancy.
ISSN:0971-5851
0975-2129
DOI:10.4103/ijmpo.ijmpo_88_17